Lifesci Capital Has Strong Estimate for CMPX FY2025 Earnings

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Lifesci Capital upped their FY2025 earnings per share (EPS) estimates for Compass Therapeutics in a note issued to investors on Tuesday, January 6th. Lifesci Capital analyst C. Zhu now expects that the company will post earnings of ($0.45) per share for the year, up from their prior forecast of ($0.50). Lifesci Capital has a “Outperform” rating and a $10.00 price objective on the stock. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.36) per share. Lifesci Capital also issued estimates for Compass Therapeutics’ Q1 2026 earnings at ($0.11) EPS, Q2 2026 earnings at ($0.11) EPS, Q4 2026 earnings at ($0.11) EPS and FY2026 earnings at ($0.46) EPS.

A number of other equities analysts also recently commented on CMPX. D. Boral Capital reiterated a “buy” rating and set a $30.00 target price on shares of Compass Therapeutics in a research note on Tuesday. Canaccord Genuity Group began coverage on Compass Therapeutics in a research report on Wednesday, December 3rd. They set a “buy” rating and a $10.00 price objective for the company. Raymond James Financial reiterated an “outperform” rating and issued a $9.00 price objective on shares of Compass Therapeutics in a report on Tuesday. Cantor Fitzgerald assumed coverage on Compass Therapeutics in a research note on Wednesday, December 3rd. They set an “overweight” rating for the company. Finally, Leerink Partnrs raised Compass Therapeutics to a “strong-buy” rating in a report on Wednesday, November 26th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Compass Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.23.

Compass Therapeutics Stock Up 3.5%

NASDAQ CMPX opened at $5.35 on Friday. Compass Therapeutics has a 52 week low of $1.33 and a 52 week high of $5.86. The firm has a 50 day moving average of $5.02 and a two-hundred day moving average of $3.92. The stock has a market capitalization of $951.55 million, a PE ratio of -11.89 and a beta of 1.45.

Compass Therapeutics (NASDAQ:CMPX) last announced its earnings results on Wednesday, November 5th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.06.

Institutional Investors Weigh In On Compass Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Strs Ohio purchased a new position in shares of Compass Therapeutics during the first quarter worth approximately $34,000. Simplicity Wealth LLC grew its position in Compass Therapeutics by 81.8% during the 2nd quarter. Simplicity Wealth LLC now owns 84,636 shares of the company’s stock worth $220,000 after purchasing an additional 38,093 shares during the last quarter. Creative Planning purchased a new position in Compass Therapeutics during the 2nd quarter worth $30,000. XTX Topco Ltd acquired a new position in Compass Therapeutics in the second quarter valued at $84,000. Finally, Invesco Ltd. raised its holdings in shares of Compass Therapeutics by 58.1% in the second quarter. Invesco Ltd. now owns 58,735 shares of the company’s stock valued at $153,000 after buying an additional 21,578 shares during the last quarter. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.